Pulmonx (NASDAQ:LUNG – Get Free Report) and Sight Sciences (NASDAQ:SGHT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.
Profitability
This table compares Pulmonx and Sight Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulmonx | -47.93% | -98.23% | -35.89% |
| Sight Sciences | -32.13% | -43.91% | -22.20% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Pulmonx and Sight Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulmonx | 1 | 0 | 3 | 0 | 2.50 |
| Sight Sciences | 1 | 2 | 5 | 0 | 2.50 |
Valuation & Earnings
This table compares Pulmonx and Sight Sciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulmonx | $90.50 million | 1.38 | -$54.00 million | ($1.01) | -2.84 |
| Sight Sciences | $77.36 million | 7.76 | -$38.43 million | ($0.52) | -20.77 |
Sight Sciences has lower revenue, but higher earnings than Pulmonx. Sight Sciences is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Pulmonx has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the S&P 500.
Insider & Institutional Ownership
91.0% of Pulmonx shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 7.5% of Pulmonx shares are held by company insiders. Comparatively, 30.4% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Sight Sciences beats Pulmonx on 9 of the 13 factors compared between the two stocks.
About Pulmonx
Pulmonx is a medical technology company focused on minimally invasive treatments for people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its products are used by clinicians to evaluate patients and provide bronchoscopic treatment. The company’s Zephyr Endobronchial Valve is a small, one-way valve placed in the lungs through a bronchoscope. By reducing airflow to targeted areas of a diseased lung, the treatment is intended to help lessen lung hyperinflation and improve the function of healthier areas.
About Sight Sciences
Sight Sciences is a medical technology company that develops and commercializes devices for ophthalmic care, with a focus on glaucoma and dry eye disease. Its products are designed to support minimally invasive procedures and address underlying causes of these conditions. The company’s portfolio includes the OMNI Surgical System, used in procedures to reduce eye pressure in patients with glaucoma, and TearCare, a device-based treatment for evaporative dry eye associated with meibomian gland dysfunction.
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.
